View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRe:NewCell 배당 및 자사주 매입배당 기준 점검 0/6Re:NewCell 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-205.6%자사주 매입 수익률총 주주 수익률-205.6%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 05Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.공시 • Jan 10Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on SalesRe:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized.공시 • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024New Risk • Dec 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr401m Forecast net loss in 2 years: kr27m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr578m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr27m net loss in 2 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (kr353.3m market cap, or US$35.3m).공시 • Dec 13Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company.Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Price Target Changed • Nov 21Price target decreased by 51% to kr40.00Down from kr81.00, the current price target is an average from 2 analysts. New target price is 363% above last closing price of kr8.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr10.55 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr331.4m to kr276.8m. EPS estimate increased from -kr10.72 to -kr10.55 per share. Chemicals industry in Sweden expected to see average net income growth of 6.4% next year. Consensus price target down from kr81.00 to kr78.50. Share price fell 4.4% to kr9.57 over the past week.분석 기사 • Nov 09Investors Give Re:NewCell AB (publ) (STO:RENEW) Shares A 84% HidingThe Re:NewCell AB (publ) ( STO:RENEW ) share price has fared very poorly over the last month, falling by a substantial...Reported Earnings • Nov 08Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Sweden.공시 • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024Major Estimate Revision • Oct 18Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr361.1m to kr331.4m. Losses expected to increase from kr8.90 per share to kr10.72. Chemicals industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr166 to kr81.00. Share price fell 84% to kr8.52 over the past week.공시 • Oct 18Re:NewCell AB (publ) Announces CEO ChangesRe:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden.Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: kr566.9m (US$51.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m).공시 • Oct 13Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million.Recent Insider Transactions • Oct 10CEO & MD recently sold kr3.5m worth of stockOn the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m.New Risk • Oct 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold).Recent Insider Transactions Derivative • Sep 06CEO & MD exercised options to buy kr35m worth of stock.On the 31st of August, Patrik Lundstrom exercised options to buy 453k shares at a strike price of around kr48.43, costing a total of kr22m. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 452.30k. Company insiders have collectively bought kr32m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Aug 30Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.3%. Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.공시 • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024Breakeven Date Change • Aug 24Forecast breakeven date pushed back to 2025The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.Major Estimate Revision • Aug 23Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr7.96 per share expected, vs -kr7.16 per share profit forecast previously. Revenue forecast reaffirmed at kr384.0m. Chemicals industry in Sweden expected to see average net income growth of 3.8% next year. Consensus price target of kr206 unchanged from last update. Share price rose 12% to kr76.55 over the past week.Recent Insider Transactions • Aug 01CEO & MD recently sold kr16m worth of stockOn the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.공시 • Jul 17Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFORe:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year.Recent Insider Transactions Derivative • Jul 10CEO & MD exercised options to buy kr17m worth of stock.On the 6th of July, Patrik Lundstrom exercised options to buy 227k shares at a strike price of around kr48.43, costing a total of kr11m. This transaction amounted to 51% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 449.50k. Company insiders have collectively bought kr26m more than they sold, via options and on-market transactions, in the last 12 months.공시 • Jul 01Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area.Major Estimate Revision • May 19Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr437.9m to kr351.4m. Forecast losses increased from -kr6.42 to -kr7.58 per share. Chemicals industry in Sweden expected to see average net income growth of 1.2% next year. Consensus price target broadly unchanged at kr198. Share price fell 3.2% to kr79.00 over the past week.Major Estimate Revision • May 10Consensus revenue estimates increase by 23%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from kr356.3m to kr437.9m. Forecast losses expected to reduce from -kr6.70 to -kr6.42 per share. Chemicals industry in Sweden expected to see average net income decline 1.1% next year. Consensus price target of kr197 unchanged from last update. Share price was steady at kr81.25 over the past week.Reported Earnings • Apr 30Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%. Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.Major Estimate Revision • Apr 27Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr6.70 per share expected, vs -kr6.02 per share profit forecast previously. Revenue forecast reaffirmed at kr370.2m. Chemicals industry in Sweden expected to see average net income decline 2.6% next year. Consensus price target down from kr220 to kr204. Share price rose 3.5% to kr76.10 over the past week.Price Target Changed • Apr 27Price target decreased by 7.6% to kr204Down from kr220, the current price target is an average from 3 analysts. New target price is 168% above last closing price of kr76.10. Stock is down 34% over the past year. The company is forecast to post a net loss per share of kr6.70 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Apr 25Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr370.2m to kr356.5m. Losses expected to increase from kr6.02 per share to kr6.70. Chemicals industry in Sweden expected to see average net income decline 2.9% next year. Consensus price target down from kr220 to kr204. Share price was steady at kr73.20 over the past week.Price Target Changed • Apr 24Price target decreased by 9.1% to kr204Down from kr224, the current price target is an average from 3 analysts. New target price is 180% above last closing price of kr72.70. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr6.02 next year compared to a net loss per share of kr8.99 last year.Major Estimate Revision • Apr 06Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr439.1m to kr370.2m. Forecast losses increased from -kr4.96 to -kr6.02 per share. Chemicals industry in Sweden expected to see average net income decline 2.2% next year. Consensus price target broadly unchanged at kr220. Share price fell 6.8% to kr76.10 over the past week.공시 • Feb 16+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023Re:NewCell AB (publ) announced that they will report Q3, 2023 results on Nov 07, 2023Breakeven Date Change • Feb 16Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr180.4m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Breakeven Date Change • Oct 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule.Reported Earnings • Oct 28Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue missed analyst estimates by 91%. Earnings per share (EPS) also missed analyst estimates by 116%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Sweden.공시 • Oct 28+ 1 more updateRe:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023Re:NewCell AB (publ) announced that they will report Q2, 2023 results on Aug 18, 2023Major Estimate Revision • Sep 02Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr8.34 per share expected, vs -kr6.87 per share profit forecast previously. Revenue forecast reaffirmed at kr133.9m. Chemicals industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target of kr275 unchanged from last update. Share price fell 6.2% to kr87.25 over the past week.Reported Earnings • Aug 26Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 3,859%, compared to a 501% growth forecast for the Chemicals industry in Sweden.Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • May 24Chief Financial Officer recently bought kr116k worth of stockOn the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares.Major Estimate Revision • May 11Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -kr5.23 to -kr6.95 per share. Revenue forecast of kr126.2m unchanged since last update. Chemicals industry in Sweden expected to see average net income growth of 8.9% next year. Consensus price target down from kr370 to kr300. Share price was steady at kr111 over the past week.Reported Earnings • May 05First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 132%. Over the next year, revenue is forecast to grow 4,106%, compared to a 422% growth forecast for the industry in Sweden.공시 • May 05Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023Price Target Changed • Apr 27Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 212% above last closing price of kr119. Stock is down 55% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Price Target Changed • Apr 06Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 190% above last closing price of kr128. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.Breakeven Date Change • Mar 09Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Recent Insider Transactions • Mar 03Chief Growth Officer recently sold kr65k worth of stockOn the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months.Major Estimate Revision • Feb 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr5.99 per share expected, vs -kr4.12 per share profit forecast previously. Revenue forecast reaffirmed at kr126.2m. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 22% to kr126 over the past week.Breakeven Date Change • Feb 19Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Reported Earnings • Feb 17Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Over the next year, revenue is forecast to grow 1,979%, compared to a 572% growth forecast for the industry in Sweden.공시 • Feb 17Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023Recent Insider Transactions Derivative • Feb 03Chief Growth Officer exercised options to buy kr1.1m worth of stock.On the 1st of February, Harald Cavalli-Bjorkman exercised options to buy 6k shares at a strike price of around kr13.54, costing a total of kr79k. This transaction amounted to 48% of their direct individual holding at the time of the trade. Since June 2021, Harald has owned 12.09k shares directly. Company insiders have collectively bought kr2.4m more than they sold, via options and on-market transactions, in the last 12 months.Breakeven Date Change • Jan 26Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Major Estimate Revision • Jan 22Consensus revenue estimates increase by 67%The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from kr5.51m to kr9.18m. Forecast losses expected to reduce from -kr3.26 to -kr3.06 per share. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 3.1% to kr175 over the past week.Recent Insider Transactions • Jan 14Chief Financial Officer recently bought kr80k worth of stockOn the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares.Breakeven Date Change • Jan 07Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.Major Estimate Revision • Dec 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr9.18m to kr6.00m. EPS estimate increased from -kr3.49 to -kr3.26 per share. Chemicals industry in Sweden expected to see average net income growth of 16% next year. Consensus price target of kr343 unchanged from last update. Share price fell 6.5% to kr214 over the past week.Recent Insider Transactions • Dec 18Chief Executive Officer recently bought kr100k worth of stockOn the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares.Recent Insider Transactions Derivative • Nov 25Plant Manager Ortviken exercised options to buy kr10m worth of stock.On the 22nd of November, Henrik Dahlbom exercised options to buy 41k shares at a strike price of around kr17.08, costing a total of kr701k. This transaction amounted to 5,861% of their direct individual holding at the time of the trade. Since June 2021, Henrik has owned 700.00 shares directly. Company insiders have collectively bought kr2.2m more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • Nov 07Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020).Major Estimate Revision • Jul 09Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -kr3.49 per share to -kr3.06 per share. Revenue forecast reaffirmed at kr9.18m. Chemicals industry in Sweden expected to see average net income growth of 25% next year. Consensus price target of kr343 unchanged from last update. Share price rose 4.8% to kr187 over the past week.Recent Insider Transactions • Jun 24Plant Manager Ortviken recently bought kr108k worth of stockOn the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 13Chief Executive Officer recently bought kr513k worth of stockOn the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.Recent Insider Transactions • May 26Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.Executive Departure • May 22Director has left the companyOn the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months.Executive Departure • May 22Director has left the companyOn the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months.Recent Insider Transactions • May 21Interim Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 RENEW 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: RENEW 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Re:NewCell 배당 수익률 vs 시장RENEW의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (RENEW)n/a시장 하위 25% (SE)1.7%시장 상위 25% (SE)4.1%업계 평균 (Chemicals)5.1%분석가 예측 (RENEW) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RENEW 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RENEW 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RENEW 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: RENEW 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YSE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/29 13:06종가2024/02/29 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Re:NewCell AB (publ)는 2명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Daniel OvinNordea MarketsJohan SpetzPareto Securities
공시 • Jun 05Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ).Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.
공시 • Jan 10Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on SalesRe:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized.
공시 • Dec 23+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2024 Results on Nov 06, 2024Re:NewCell AB (publ) announced that they will report Q3, 2024 results on Nov 06, 2024
New Risk • Dec 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr401m Forecast net loss in 2 years: kr27m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr578m free cash flow). Share price has been highly volatile over the past 3 months (33% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr27m net loss in 2 years). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (kr353.3m market cap, or US$35.3m).
공시 • Dec 13Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company.
Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 24Forecast to breakeven in 2025The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Price Target Changed • Nov 21Price target decreased by 51% to kr40.00Down from kr81.00, the current price target is an average from 2 analysts. New target price is 363% above last closing price of kr8.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of kr10.55 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr331.4m to kr276.8m. EPS estimate increased from -kr10.72 to -kr10.55 per share. Chemicals industry in Sweden expected to see average net income growth of 6.4% next year. Consensus price target down from kr81.00 to kr78.50. Share price fell 4.4% to kr9.57 over the past week.
분석 기사 • Nov 09Investors Give Re:NewCell AB (publ) (STO:RENEW) Shares A 84% HidingThe Re:NewCell AB (publ) ( STO:RENEW ) share price has fared very poorly over the last month, falling by a substantial...
Reported Earnings • Nov 08Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Sweden.
공시 • Nov 07Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024
Major Estimate Revision • Oct 18Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr361.1m to kr331.4m. Losses expected to increase from kr8.90 per share to kr10.72. Chemicals industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr166 to kr81.00. Share price fell 84% to kr8.52 over the past week.
공시 • Oct 18Re:NewCell AB (publ) Announces CEO ChangesRe:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden.
Breakeven Date Change • Oct 16Forecast breakeven date pushed back to 2025The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule.
New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: kr566.9m (US$51.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m).
공시 • Oct 13Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million.
Recent Insider Transactions • Oct 10CEO & MD recently sold kr3.5m worth of stockOn the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m.
New Risk • Oct 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold).
Recent Insider Transactions Derivative • Sep 06CEO & MD exercised options to buy kr35m worth of stock.On the 31st of August, Patrik Lundstrom exercised options to buy 453k shares at a strike price of around kr48.43, costing a total of kr22m. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 452.30k. Company insiders have collectively bought kr32m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Aug 30Second quarter 2023 earnings: EPS misses analyst expectationsSecond quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.3%. Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.
공시 • Aug 30+ 2 more updatesRe:NewCell AB (publ) to Report Q4, 2023 Results on Feb 13, 2024Re:NewCell AB (publ) announced that they will report Q4, 2023 results on Feb 13, 2024
Breakeven Date Change • Aug 24Forecast breakeven date pushed back to 2025The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule.
Major Estimate Revision • Aug 23Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr7.96 per share expected, vs -kr7.16 per share profit forecast previously. Revenue forecast reaffirmed at kr384.0m. Chemicals industry in Sweden expected to see average net income growth of 3.8% next year. Consensus price target of kr206 unchanged from last update. Share price rose 12% to kr76.55 over the past week.
Recent Insider Transactions • Aug 01CEO & MD recently sold kr16m worth of stockOn the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
공시 • Jul 17Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFORe:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year.
Recent Insider Transactions Derivative • Jul 10CEO & MD exercised options to buy kr17m worth of stock.On the 6th of July, Patrik Lundstrom exercised options to buy 227k shares at a strike price of around kr48.43, costing a total of kr11m. This transaction amounted to 51% of their direct individual holding at the time of the trade. Since December 2022, Patrik's direct individual holding has decreased from 814.21k shares to 449.50k. Company insiders have collectively bought kr26m more than they sold, via options and on-market transactions, in the last 12 months.
공시 • Jul 01Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area.
Major Estimate Revision • May 19Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr437.9m to kr351.4m. Forecast losses increased from -kr6.42 to -kr7.58 per share. Chemicals industry in Sweden expected to see average net income growth of 1.2% next year. Consensus price target broadly unchanged at kr198. Share price fell 3.2% to kr79.00 over the past week.
Major Estimate Revision • May 10Consensus revenue estimates increase by 23%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from kr356.3m to kr437.9m. Forecast losses expected to reduce from -kr6.70 to -kr6.42 per share. Chemicals industry in Sweden expected to see average net income decline 1.1% next year. Consensus price target of kr197 unchanged from last update. Share price was steady at kr81.25 over the past week.
Reported Earnings • Apr 30Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%. Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden.
Major Estimate Revision • Apr 27Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 losses of -kr6.70 per share expected, vs -kr6.02 per share profit forecast previously. Revenue forecast reaffirmed at kr370.2m. Chemicals industry in Sweden expected to see average net income decline 2.6% next year. Consensus price target down from kr220 to kr204. Share price rose 3.5% to kr76.10 over the past week.
Price Target Changed • Apr 27Price target decreased by 7.6% to kr204Down from kr220, the current price target is an average from 3 analysts. New target price is 168% above last closing price of kr76.10. Stock is down 34% over the past year. The company is forecast to post a net loss per share of kr6.70 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Apr 25Consensus EPS estimates fall by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr370.2m to kr356.5m. Losses expected to increase from kr6.02 per share to kr6.70. Chemicals industry in Sweden expected to see average net income decline 2.9% next year. Consensus price target down from kr220 to kr204. Share price was steady at kr73.20 over the past week.
Price Target Changed • Apr 24Price target decreased by 9.1% to kr204Down from kr224, the current price target is an average from 3 analysts. New target price is 180% above last closing price of kr72.70. Stock is down 42% over the past year. The company is forecast to post a net loss per share of kr6.02 next year compared to a net loss per share of kr8.99 last year.
Major Estimate Revision • Apr 06Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr439.1m to kr370.2m. Forecast losses increased from -kr4.96 to -kr6.02 per share. Chemicals industry in Sweden expected to see average net income decline 2.2% next year. Consensus price target broadly unchanged at kr220. Share price fell 6.8% to kr76.10 over the past week.
공시 • Feb 16+ 1 more updateRe:NewCell AB (publ) to Report Q3, 2023 Results on Nov 07, 2023Re:NewCell AB (publ) announced that they will report Q3, 2023 results on Nov 07, 2023
Breakeven Date Change • Feb 16Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr180.4m in 2024. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Breakeven Date Change • Oct 29Forecast breakeven date pushed back to 2024The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule.
Reported Earnings • Oct 28Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue missed analyst estimates by 91%. Earnings per share (EPS) also missed analyst estimates by 116%. Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Chemicals industry in Sweden.
공시 • Oct 28+ 1 more updateRe:NewCell AB (publ) to Report Q2, 2023 Results on Aug 18, 2023Re:NewCell AB (publ) announced that they will report Q2, 2023 results on Aug 18, 2023
Major Estimate Revision • Sep 02Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr8.34 per share expected, vs -kr6.87 per share profit forecast previously. Revenue forecast reaffirmed at kr133.9m. Chemicals industry in Sweden expected to see average net income growth of 6.7% next year. Consensus price target of kr275 unchanged from last update. Share price fell 6.2% to kr87.25 over the past week.
Reported Earnings • Aug 26Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Revenue missed analyst estimates by 19%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 3,859%, compared to a 501% growth forecast for the Chemicals industry in Sweden.
Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • May 24Chief Financial Officer recently bought kr116k worth of stockOn the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares.
Major Estimate Revision • May 11Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -kr5.23 to -kr6.95 per share. Revenue forecast of kr126.2m unchanged since last update. Chemicals industry in Sweden expected to see average net income growth of 8.9% next year. Consensus price target down from kr370 to kr300. Share price was steady at kr111 over the past week.
Reported Earnings • May 05First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 132%. Over the next year, revenue is forecast to grow 4,106%, compared to a 422% growth forecast for the industry in Sweden.
공시 • May 05Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023
Price Target Changed • Apr 27Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 212% above last closing price of kr119. Stock is down 55% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Price Target Changed • Apr 06Price target increased to kr370Up from kr338, the current price target is an average from 2 analysts. New target price is 190% above last closing price of kr128. Stock is down 47% over the past year. The company is forecast to post a net loss per share of kr5.23 next year compared to a net loss per share of kr4.33 last year.
Breakeven Date Change • Mar 09Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Recent Insider Transactions • Mar 03Chief Growth Officer recently sold kr65k worth of stockOn the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months.
Major Estimate Revision • Feb 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 losses of -kr5.99 per share expected, vs -kr4.12 per share profit forecast previously. Revenue forecast reaffirmed at kr126.2m. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 22% to kr126 over the past week.
Breakeven Date Change • Feb 19Forecast breakeven date moved forward to 2023The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Reported Earnings • Feb 17Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 32%. Over the next year, revenue is forecast to grow 1,979%, compared to a 572% growth forecast for the industry in Sweden.
공시 • Feb 17Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023
Recent Insider Transactions Derivative • Feb 03Chief Growth Officer exercised options to buy kr1.1m worth of stock.On the 1st of February, Harald Cavalli-Bjorkman exercised options to buy 6k shares at a strike price of around kr13.54, costing a total of kr79k. This transaction amounted to 48% of their direct individual holding at the time of the trade. Since June 2021, Harald has owned 12.09k shares directly. Company insiders have collectively bought kr2.4m more than they sold, via options and on-market transactions, in the last 12 months.
Breakeven Date Change • Jan 26Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Major Estimate Revision • Jan 22Consensus revenue estimates increase by 67%The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from kr5.51m to kr9.18m. Forecast losses expected to reduce from -kr3.26 to -kr3.06 per share. Chemicals industry in Sweden expected to see average net income growth of 15% next year. Consensus price target of kr343 unchanged from last update. Share price fell 3.1% to kr175 over the past week.
Recent Insider Transactions • Jan 14Chief Financial Officer recently bought kr80k worth of stockOn the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares.
Breakeven Date Change • Jan 07Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Jan 01Forecast to breakeven in 2024The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule.
Major Estimate Revision • Dec 21Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from kr9.18m to kr6.00m. EPS estimate increased from -kr3.49 to -kr3.26 per share. Chemicals industry in Sweden expected to see average net income growth of 16% next year. Consensus price target of kr343 unchanged from last update. Share price fell 6.5% to kr214 over the past week.
Recent Insider Transactions • Dec 18Chief Executive Officer recently bought kr100k worth of stockOn the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares.
Recent Insider Transactions Derivative • Nov 25Plant Manager Ortviken exercised options to buy kr10m worth of stock.On the 22nd of November, Henrik Dahlbom exercised options to buy 41k shares at a strike price of around kr17.08, costing a total of kr701k. This transaction amounted to 5,861% of their direct individual holding at the time of the trade. Since June 2021, Henrik has owned 700.00 shares directly. Company insiders have collectively bought kr2.2m more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • Nov 07Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020)Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020).
Major Estimate Revision • Jul 09Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -kr3.49 per share to -kr3.06 per share. Revenue forecast reaffirmed at kr9.18m. Chemicals industry in Sweden expected to see average net income growth of 25% next year. Consensus price target of kr343 unchanged from last update. Share price rose 4.8% to kr187 over the past week.
Recent Insider Transactions • Jun 24Plant Manager Ortviken recently bought kr108k worth of stockOn the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 13Chief Executive Officer recently bought kr513k worth of stockOn the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months.
Recent Insider Transactions • May 26Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.
Executive Departure • May 22Director has left the companyOn the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months.
Executive Departure • May 22Director has left the companyOn the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months.
Recent Insider Transactions • May 21Interim Chief Financial Officer recently bought kr55k worth of stockOn the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months.